Tumour molecular profiling for deciding therapy—the French initiative
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumour molecular profiling for deciding therapy—the French initiative
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 9, Issue 8, Pages 479-486
Publisher
Springer Nature
Online
2012-07-10
DOI
10.1038/nrclinonc.2012.42
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- (2012) Doron Lipson et al. NATURE MEDICINE
- Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology
- (2011) Maureen Cronin et al. Biomarkers in Medicine
- Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
- (2011) Gilberto de Lima Lopes et al. CANCER
- KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective
- (2011) P. R. Blank et al. CLINICAL CANCER RESEARCH
- Current technologies for HER2 testing in breast cancer
- (2011) C.B. Moelans et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
- (2011) I. Borget et al. EUROPEAN RESPIRATORY JOURNAL
- Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
- (2011) Qing Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice
- (2011) Leina Sun et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- A Multiplex SNaPshot Assay as a Rapid Method for Detecting KRAS and BRAF Mutations in Advanced Colorectal Cancers
- (2011) Sandrine Magnin et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor Kinase Inhibitors
- (2011) Rama Krishna Kancha et al. Journal of Thoracic Oncology
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
- (2011) Hiroyuki Yasuda et al. LANCET ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice
- (2010) Magnus Sundström et al. BMC CANCER
- Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
- (2010) Elias Jabbour et al. CANCER
- Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations
- (2010) Athanasios C. Tsiatis et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer
- (2010) Sarah Park et al. Journal of Thoracic Oncology
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
- (2010) Steven JM Jones et al. GENOME BIOLOGY
- Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors
- (2009) E. E. Mancl et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array
- (2009) F. Andre et al. CLINICAL CANCER RESEARCH
- Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
- (2009) Tony S.K. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
- (2009) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis
- (2009) E S K Ma et al. JOURNAL OF CLINICAL PATHOLOGY
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
- (2009) A Hochhaus et al. LEUKEMIA
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
- (2009) Laura E. MacConaill et al. PLoS One
- Survie à cinq ans des cancers bronchiques primitifs dans les centres hospitaliers généraux
- (2009) M. Grivaux et al. REVUE DES MALADIES RESPIRATOIRES
- Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer
- (2008) C.-H. Gow et al. ANNALS OF ONCOLOGY
- KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition
- (2008) E Rouleau et al. BRITISH JOURNAL OF CANCER
- Emerging ethnic differences in lung cancer therapy
- (2008) I Sekine et al. BRITISH JOURNAL OF CANCER
- Cancer driver mutations in protein kinase genes
- (2008) Ali Torkamani et al. CANCER LETTERS
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
- (2008) Timothy J. Ley et al. NATURE
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started